What smart money is saying about IDEXX Laboratories
6 funds in our archive have pitched IDEXX Laboratories, most recently Jensen Investment Management Quality Growth Equity Composite in June 2026.
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
Get an email when a fund buys, sells or pitches it
Fund signal · last 12 months
12 lettersFunds are split between buying and selling
Moves described in fund letters in our archive. A sentence published word for word by several funds of one house in the same quarter counts once.
Position history
Between Q4 2024 and Q3 2026, 16 fund letters reported a position in IDEXX Laboratories, with 5 buys (opened or added) and 2 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 1 | 0 | 0 |
| Q2 2026 | 10 | 2 | 2 | 1 |
| Q1 2026 | 1 | 0 | 0 | 0 |
| Q4 2025 | 0 | 0 | 0 | 1 |
| Q3 2025 | 2 | 0 | 0 | 0 |
| Q2 2025 | 1 | 1 | 0 | 2 |
| Q1 2025 | 1 | 1 | 0 | 1 |
| Q4 2024 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 16 positions · 7 moves
- September 2026
“We also added to TJX Companies (TJX), Cintas Corporation (CTAS), and IDEXX Laboratories (IDXX), building up positions we initiated during the second quarter.”
IDEXX Laboratories - TrimmedFundsmith Equity FundJune 2026
“The five biggest detractors from our Fund’s performance during the period were: Stock Attribution LVMH -1.4% Zoetis -1.1% IDEXX -1.1% Microsoft -1.0% Coloplast -0.9% Source: State Street 10 Coloplast, LVMH and Zoetis have been sold for the reasons given in Appendix 2. We have reduced our stakes in IDEXX on valuation grounds and in Microsoft.”
IDEXX Laboratories - New positionBaillie Gifford US Equity GrowthJune 2026
“We have continued to broaden the portfolio's enduring growth exposure with new purchases in IDEXX and Mastercard.”
IDEXX Laboratories - June 2026
Listed in Baron Health Care Fund’s reported holdings.
IDEXX Laboratories - June 2026
Listed in Baron First Principles ETF’s reported holdings.
IDEXX Laboratories - HoldsBaron Partners FundJune 2026
Listed in Baron Partners Fund’s reported holdings.
IDEXX Laboratories - TrimmedBaron Asset FundJune 2026
“Top net sales for the quarter Quarter End Market Cap or Market Cap When Sold ($B) Net Amount Sold ($M) Fair Isaac Corporation 27.7 23.1 Floor & Decor Holdings, Inc. 5.2 14.3 Booz Allen Hamilton Holding Corporation 7.3 9.7 Amphenol Corporation 216.9 8.9 Gartner, Inc. 8.7 7.5 We reduced our position in Fair Isaac Corporation , which produces the FICO score that is widely used by lenders to evaluate consumers’ creditworthiness, in response to ongoing uncertainty about potential regulatory changes in the mortgage market. We sold our position in Floor & Decor Holdings, Inc. , a retailer of home flooring, over concerns that market demand trends will remain depressed for longer than we had expected. We reduced our position in Booz Allen Hamilton Holding Corporation , which primarily provides technology consulting and implementation services to the U.S. defense establishment, over concerns about the looming impact of AI on their business. We managed down the Fund’s weightings in several long-held positions, including Amphenol Corporation , Gartner, Inc. , IDEXX Laboratories, Inc. , and Hyatt Hotels Corporation .”
IDEXX Laboratories - HoldsBaron Partners FundJune 2026
Listed in Baron Partners Fund’s reported holdings.
IDEXX Laboratories - HoldsBaron CapitalJune 2026
Listed in Baron Capital’s reported holdings.
IDEXX Laboratories - June 2026
“Veterinary diagnostics leader IDEXX Laboratories also made the quarterly detractors list despite posting strong quarterly results.”
IDEXX Laboratories - June 2026
“Portfolio Activity In Q2 2026, we initiated new positions in GE Aerospace, GE Vernova, Howmet Aerospace, Hermès International, Keyence, and Rheinmetall while selling our holdings in Boston Scientific, Siemens Healthineers, and Zoetis. During the period we also added to our positions in ASML and Idexx Labs and trimmed our positions in Starbucks, Oracle, Shopify, Aon and Broadcom.”
IDEXX Laboratories - HoldsBaron Growth FundMarch 2026
“Top performing stocks owned more than 10 years Year Acquired Cumulative Return Since Date Acquired (%) Annualized Return Since Date Acquired (%) IDEXX Laboratories, Inc. 2005 3,804.0 18.9”
IDEXX Laboratories - HoldsConestogaSeptember 2025
“2. IDEXX Laboratories, Inc. (IDXX) IDXX is the industry leader in providing instruments (and consumables) used in diagnostics, detection, and information systems for veterinary, food, and water testing applications.”
IDEXX Laboratories - September 2025
“IDEXX Laboratories Inc. develops, manufactures, and distributes products and services for animal veterinary, livestock, poultry, and water testing markets.”
IDEXX Laboratories - New positionPlatinium AMJune 2025
“Commentary – of chicken wings and healthy pets Following the announcement of the new US tariffs in early April, markets experienced a sharp but brief sell-off. The administration’s subsequent messaging about negotiating trade deals to wind back these tariffs quickly calmed markets. We used the narrow window of opportunity opened by this disruption to initiate two new positions: Wingstop and IDEXX Laboratories.”
IDEXX Laboratories - New positionMacquarie Large Cap Growth FundMarch 2025
“We took advantage of weakness in shares to start a position.”
IDEXX Laboratories
Fund coverage · 6 theses
IDEXX Laboratories has durable competitive advantages, high recurring revenue, and strong long-term compounding potential.
Read the full thesis- Baron Growth FundDecember 2025
IDEXX Laboratories, Inc. is a veterinary diagnostics leader with strong execution, proprietary innovation, and secular pet-care tailwinds supporting durable growth.
Read the full thesis - Polen Global GrowthJune 2025
Backed by dominant market share and recurring revenues, IDEXX Labs offers long-term growth potential in pet diagnostics with defensive traits and renewed valuation appeal as pandemic-era pet care demand begins to normalize.
Read the full thesis - Platinium AMJune 2025
IDEXX is a leading global provider of veterinary diagnostics and software, enabling veterinarians to deliver rapid, in-clinic testing while generating continuous revenue through high-margin consumables.
Read the full thesis - Macquarie Large Cap Growth FundMarch 2025
IDEXX Laboratories Inc. is an animal health company poised for growth as the demand for veterinary services and diagnostics increases following the pandemic pet boom.
Read the full thesis - Baron Focused Growth FundDecember 2024
IDEXX Laboratories, Inc. is expected to achieve accelerated growth and strong financial performance due to the pandemic-driven increase in pet ownership, improved foot traffic, and its significant pricing power.
Read the full thesis
Read every full thesis on IDEXX Laboratories
Read all 6 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→